Microfluidic-Enabled Intracellular Delivery of Membrane Impermeable Inhibitors to Study Target Engagement in Human Primary Cells
journal contributionposted on 2017-10-31, 00:00 authored by Jing Li, Bu Wang, Brian M. Juba, Michael Vazquez, Steve W. Kortum, Betsy S. Pierce, Michael Pacheco, Lee Roberts, Joseph W. Strohbach, Lyn H. Jones, Erik Hett, Atli Thorarensen, Jean-Baptiste Telliez, Armon Sharei, Mark Bunnage, Jonathan Brian Gilbert
Biochemical screening is a major source of lead generation for novel targets. However, during the process of small molecule lead optimization, compounds with excellent biochemical activity may show poor cellular potency, making structure–activity relationships difficult to decipher. This may be due to low membrane permeability of the molecule, resulting in insufficient intracellular drug concentration. The Cell Squeeze platform increases permeability regardless of compound structure by mechanically disrupting the membrane, which can overcome permeability limitations and bridge the gap between biochemical and cellular studies. In this study, we show that poorly permeable Janus kinase (JAK) inhibitors are delivered into primary cells using Cell Squeeze, inhibiting up to 90% of the JAK pathway, while incubation of JAK inhibitors with or without electroporation had no significant effect. We believe this robust intracellular delivery approach could enable more effective lead optimization and deepen our understanding of target engagement by small molecules and functional probes.
JAK pathwayCell Squeezecompound structureJanus kinaseMembrane Impermeable Inhibitorsintracellular delivery approachJAK inhibitorsCells Biochemical screeningnovel targetspermeability limitationsmoleculeStudy Target EngagementCell Squeeze platform increases permeabilitymembrane permeabilityintracellular drug concentrationoptimizationMicrofluidic-Enabled Intracellular Deliverytarget engagement